Clinical Medicine V. (Poster discussion will take place in the Aula during the Coffee Break)
Dr. Gonczi, Lorant, PhD
Department of Internal Medicine and Oncology, Semmelweis University
+36308208250
lorantgonczi@gmail.com
Incidence, prevalence, disease course and treatment strategy of Crohn’s disease patients in Western Hungary – a population-based inception cohort study between 2007 and 2018, data from the Veszprem County cohort
Lorant Gonczi1, Laszlo Lakatos2, Zsuzsanna Kurti1, Petra Golovics3, Tunde Pandur4, Gyula David2, Zsuzsanna Erdelyi2, Istvan Szita2, Peter L. Lakatos1,5
1. Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary
2. Department of Gastroenterology, Ferenc Csolnoky Hospital, Veszprem, Hungary
3. Department of Gastroenterology, Hungarian Defence Forces Medical Centre, Budapest, Hungary
4. Department of Gastroenterology, Grof Eszterhazy Hospital, Papa, Hungary
5. Division of Gastroenterology, McGill University Health Center, Montreal, Quebec, Canada
Poszter
Clinical Medicine V. (Poster discussion will take place in the Aula during the Coffee Break)
English
Clinical Medicine
Background:
The number of prospective population-based studies of Crohn’s disease(CD) patients is still limited from Eastern Europe. The present study is a continuation of the Veszprem IBD cohort with a follow-up since 1977.
Aim:
Our aim was to analyze the incidence and prevalence rates, disease phenotype at diagnosis, treatment strategy, disease course and surgical outcomes in a prospective population-based study including incident CD patients diagnosed between 2007 and 2018.
Methods:
Data of 421 patients were analyzed (male/female: 237/184; mean age at diagnosis: 33.3±16.2 years). Both in-hospital and outpatient records were collected and comprehensively reviewed. The source of age- and gender-specific demographic data was derived from the Hungarian Central Statistical Office.
Results:
Adjusted mean incidence rate was 9.94 (CI95%: 9.0-10.9) /105 person-years in this 12 year period. Prevalence rate was 236.78 (CI95%: 220.8-252.8) in 2015. Stenosing (B2) or penetrating (B3) disease behavior was present in 17.6% and 20.0% of the patients at diagnosis, while perianal disease in 13.5%. The probability of disease behavior progression from luminal into stenosing or penetrating phenotype was 12.2% (SE:2.0) at 3 years and 22.0% (SE:3.0) at 10 years. Distribution of maximal therapeutic steps during the total follow-up (8.53y, SD: 3.3) were 5-ASA in 15.7%, systemic corticosteroids in 14.3%, immunosuppressive therapy in 42.5%; biologic therapy in 26.2%. The Probability of receiving biological therapy after diagnosis was 20.9% (SE:2.0) at 5 years and 28.8% (SE:2.0) at 10 years. The probability of first resective surgery was 20.7% (SE:2.0) at 1 year, 26.1% (SE:2.2) at 5 years and 30.7% (SE:2.4) at 10 years.
Conclusions:
The incidence of CD in this period was high, similar to high-incidence areas in Western Europe and to our previous data from the Veszprem cohort. Distribution of maximal treatment steps is in line with the biological era. Disease behavior progression was lower compared to data from previous decades, while long-term (10y) surgery rates also decreased.
Fundung: post-doctorial ÚNKP-21-4-II-SE-31
Other, please specify in the next box
Semmelweis University, post-doctoral UNKP
Gönczi Lóránt
I give consent to the publication of my abstract on the website of the congress.
Szabad
elfogadva
poszter
nem rendelkezett róla
1103
10:30
10:35
Lorant Gonczi1, Laszlo Lakatos2, Zsuzsanna Kurti1, Petra Golovics3, Tunde Pandur4, Gyula David2, Zsuzsanna Erdelyi2, Istvan Szita2, Peter L. Lakatos1,5
1. Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary
2. Department of Gastroenterology, Ferenc Csolnoky Hospital, Veszprem, Hungary
3. Department of Gastroenterology, Hungarian Defence Forces Medical Centre, Budapest, Hungary
4. Department of Gastroenterology, Grof Eszterhazy Hospital, Papa, Hungary
5. Division of Gastroenterology, McGill University Health Center, Montreal, Quebec, Canada